-
1.发明授权公开(公告)号：US09682138B2
公开(公告)日：2017-06-20
申请号：US14616042
申请日：2015-02-06
申请人： MERIAL LIMITED , Centre National De la Recherche Scientifique , Institut Gustave Roussy , Universite Paris-Sud
发明人： Herve Poulet , Thierry Heidmann
IPC分类号： A61K39/21 , A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/552 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N2710/24043 , C12N2740/13034 , C12N2740/13071
摘要： The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
-
2.发明申请Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene 有权含有优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗公开(公告)号：US20150283228A1
公开(公告)日：2015-10-08
申请号：US14616042
申请日：2015-02-06
申请人： Merial Limited , Centre National De la Recherche Scientifique , Institut Gustave Roussy , Universite Paris-Sud
发明人： Herve Poulet , Thierry Heidmann
IPC分类号： A61K39/21 , C12N7/00 , C07K14/005
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/552 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N2710/24043 , C12N2740/13034 , C12N2740/13071
摘要： The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
摘要翻译： 本发明提供载体，其含有并表达体内或体外FeLV抗原，其在动物或人体内针对FeLV引起免疫应答，包含所述载体和/或FeLV多肽的组合物，针对FeLV的疫苗接种方法以及用于其的试剂盒 方法和组成。
-
3.发明授权公开(公告)号：US09856295B2
公开(公告)日：2018-01-02
申请号：US14507455
申请日：2014-10-06
申请人： MERIAL LIMITED , Centre National De la Recherche Scientifique , Institut Gustave Roussy , Universite Paris-Sud
发明人： Herve Poulet , Thierry Heidmann
IPC分类号： C07K14/005 , C07K14/15 , C12N7/00 , C12N15/86 , A61K31/04 , A61K38/16 , A61K39/12 , A61K39/21 , A61K39/275 , A61K39/00
CPC分类号： C07K14/005 , A61K31/04 , A61K38/162 , A61K39/12 , A61K39/21 , A61K39/275 , A61K2039/5256 , A61K2039/53 , A61K2039/70 , A61K2300/00 , C07K14/15 , C12N7/00 , C12N15/86 , C12N2710/24043 , C12N2710/24044 , C12N2740/13022 , C12N2740/13034 , C12N2800/22
摘要： The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
-
4.发明申请公开(公告)号：US20150030623A1
公开(公告)日：2015-01-29
申请号：US14507455
申请日：2014-10-06
申请人： Merial Limited , Centre National De la Recherche Scientifique , Institut Gustave Roussy , Universite Paris-Sud
发明人： Herve Poulet , Thierry Heidmann
IPC分类号： C07K14/005 , C12N7/00 , C12N15/86
CPC分类号： C07K14/005 , A61K31/04 , A61K38/162 , A61K39/12 , A61K39/21 , A61K39/275 , A61K2039/5256 , A61K2039/53 , A61K2039/70 , A61K2300/00 , C07K14/15 , C12N7/00 , C12N15/86 , C12N2710/24043 , C12N2710/24044 , C12N2740/13022 , C12N2740/13034 , C12N2800/22
摘要： The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
-
公开(公告)号：US09974852B2
公开(公告)日：2018-05-22
申请号：US14896505
申请日：2014-06-06
申请人： VIROXIS S.A.S. , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT GUSTAVE ROUSSY , UNIVERSITE PARIS-SUD XI
发明人： Thierry Heidmann
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/552 , A61K2039/572 , C07K14/005 , C12N2740/15022 , C12N2740/15034
摘要： A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
-
公开(公告)号：US20140294880A1
公开(公告)日：2014-10-02
申请号：US14363095
申请日：2012-12-07
申请人： VIROXIS S.A.S. , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE PARIS-SUD XI , INSTITUT GUSTAVE ROUSSY
发明人： Thierry Heidmann
IPC分类号： A61K39/21 , C07K14/005
CPC分类号： A61K39/21 , A61K39/12 , C07K14/005 , C12N2740/15022 , C12N2740/15034 , C12N2740/16122 , C12N2740/16134
摘要： A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
摘要翻译： 作为活性物质的药物组合物包括与药学上可接受的载体结合的基本上缺乏免疫抑制性质的突变型慢病毒ENV蛋白或上述蛋白质的片段的突变慢病毒ENV蛋白的活性物质。
-
公开(公告)号：US09636396B2
公开(公告)日：2017-05-02
申请号：US13707885
申请日：2012-12-07
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE PARIS-SUD XI , INSTITUT GUSTAVE ROUSSY , VIROXIS S.A.S.
发明人： Thierry Heidmann
CPC分类号： A61K39/12 , A61K39/21 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/162 , C12N2740/15022 , C12N2740/15033 , C12N2740/15034 , C12N2740/16022 , C12N2740/16034 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134
摘要： A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
-
公开(公告)号：US09682137B2
公开(公告)日：2017-06-20
申请号：US14363095
申请日：2012-12-07
申请人： VIROXIS S.A.S. , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE PARIS-SUD XI , INSTITUT GUSTAVE ROUSSY
发明人： Thierry Heidmann
IPC分类号： A61K39/12 , A61K39/21 , C07K14/005
CPC分类号： A61K39/21 , A61K39/12 , C07K14/005 , C12N2740/15022 , C12N2740/15034 , C12N2740/16122 , C12N2740/16134
摘要： A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.027 秒)
